BioPharmSignal logoBioPharmSignal

Biotech News

Xenon to Present at Upcoming Investor Conferences

Xenon (XENE)XenonCompany update

VANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced

Related news

XENEXenon2026-09-21 20:01 EST

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

XENEXenon2026-09-03 20:01 EST

Xenon to Present at Wells Fargo Healthcare Conference

ALKSAlkermes plc2026-11-03 21:00 EST

Alkermes to Present at Upcoming Investor Conferences

CLNNClene Inc.2026-09-22 12:00 EST

Clene to Present at Upcoming Investor Conferences

CLNNClene Inc.2026-09-03 12:00 EST

Clene to Present at Upcoming September Investor Conferences

NBIXNeurocrine Biosciences2026-09-02 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

VYGRVoyager Therapeutics2026-09-01 12:00 EST

Voyager to Present at Upcoming Investor Conferences

AXSMAxsome2026-11-03 12:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

IKTInhibikase Therapeutics2026-10-27 12:00 EST

Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026

ABOSAcumen Pharmaceuticals2026-09-02 20:00 EST

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

View all latest news

Xenon

Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....

Recent company news

XENEXenon2026-11-03 21:01 EST

Xenon to Present at Upcoming Investor Conferences

XENEXenon2026-11-02 21:02 EST

Xenon to Report Q3 2026 Financial Results on November 9, 2026

XENEXenon2026-10-30 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-10-29 12:30 EST

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

XENEXenon2026-10-02 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
37.68 USD
Market cap
5.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States